TTC28-AS1: A Potential Drug Target and Biomarker (G284900)

Target Name: TTC28-AS1

NCBI ID: G284900

Other Name(s): TTC28-AS | TTC28 antisense RNA 1, transcript variant 1 | TTC28 antisense RNA 1 | TTC28AS | dJ353E16.2

TTC28-AS1: A Potential Drug Target and Biomarker

TTC28-AS1, short for Trans-Actinin-Cysteinyl-Lysine 28-Amide, is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and liver. It is a member of the actinin family, which is a group of proteins that play a critical role in cell signaling and structure. TTC28-AS1 has been identified as a potential drug target and biomarker due to its unique structure and the involvement of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The actinin family is characterized by the presence of a unique domain that is composed of a series of amino acids that are involved in the formation of a helical structure. This domain is known as the actinin alpha-helices, and it is the source of the protein's unique structure and stability. TTC28-AS1 is characterized by the presence of an actinin alpha-helix that is composed of four amino acids: alanine, glutamic acid, aspartic acid, and glycine.

One of the key features of TTC28-AS1 is its ability to interact with various signaling molecules, including neurotransmitters and cytokines. This interaction allows TTC28-AS1 to play a critical role in cell signaling and communication. In fact, TTC28-AS1 has been shown to interact with several neurotransmitters, including dopamine, serotonin, and endothelial nitric oxide (NO).

TTC28-AS1's involvement in neurotransmission makes it a potential drug target for a variety of neurological and psychiatric disorders. For example, TTC28-AS1 has been shown to be involved in the development and progression of several neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. In addition, TTC28-AS1 has also been shown to be involved in the development of anxiety and depression, as well as several other psychiatric disorders.

Another potential role for TTC28-AS1 as a drug target is its involvement in cancer. TTC28-AS1 has been shown to be involved in the development and progression of several types of cancer, including breast, ovarian, and prostate cancer. In addition, TTC28-AS1 has also been shown to play a critical role in the regulation of cell growth and apoptosis, which are processes that are often disrupted in cancer cells.

In addition to its potential as a drug target, TTC28-AS1 has also been identified as a potential biomarker for several diseases. For example, TTC28-AS1 has been shown to be involved in the regulation of inflammation, which is a critical factor in the development and progression of several diseases, including cancer and neurodegenerative disorders. In addition, TTC28-AS1 has also been shown to play a critical role in the regulation of cell signaling and communication, which is often disrupted in these diseases.

The identification of TTC28-AS1 as a potential drug target and biomarker has significant implications for the development of new treatments for a variety of neurological and psychiatric disorders. Further research is needed to fully understand the role of TTC28-AS1 in cell signaling and communication, as well as its potential as a drug target and biomarker. However, the unique structure and function of TTC28-AS1 make it an intriguing candidate for further study and potential clinical applications.

Protein Name: TTC28 Antisense RNA 1

More Common Targets